MEGLUMINE ACRIDONE ACETATE (CYCLOFERON) FOR COVID-19
Date of publication: April 7, 2020
Objectives:
- To search and synthesize information on the market approval of MA in different settings.
- To search for existing COVID-19 treatment guidelines (TGs) or clinical practice guidelines (CPG) recommending its use, as well as existing evidence on its clinical efficacy, safety and cost-effectiveness.
Evidence summary:
Rapid review:
Use of Meglumine acridone acetate (MA) for treating patients with COVID-19